跳至主要内容

Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials

 On July 20, 2023, the clinical trial application of YY201, a dual-function phosphorylation site-targeted inhibitor of STAT3 independently developed by Yuyao Biotech, was officially approved by the National Medical Products Administration (NMPA).  The indications are advanced solid tumors and relapsed and refractory hematologic malignancies.

Shanghai Medicilon Inc. (Medicilon), as a partner of Yuyao Biotech, provided YY201 with pharmaceutical research services (including raw materials and preparations), preclinical research services (including drug efficacy, pharmacokinetics, safety evaluation) and IND declaration services, helping YY201 successfully pass IND approval and enter the clinical trial stage.

Due to its relatively flat target interface, STAT3 cannot provide a "pocket" structure for specific binding of small molecules, and is recognized as a "druggable target".  The team of Yuyao biological scientists has been focusing on the basic and translational research of STAT3 targets, and with the help of AI technology, it has discovered and developed a nanomolar STAT3 dual phosphorylation site inhibitor for the first time, a world-leading First-in-class small molecule target drug "YY201".  The drug directly binds to STAT3, inhibits the Tyr705 and Ser727 double-site phosphorylation of STAT3, inhibits STAT3 function and blocks downstream signal transmission, thereby exerting a tumor-suppressing effect.  In vitro pharmacology and pharmacodynamics studies have shown that the affinity activity of YY201 and STAT3 is 1-10 nanomolar, and it is effective in pancreatic cancer, triple-negative breast cancer, lung cancer, acute myeloid leukemia, lymphoma and other solid tumors and blood tumors in vitro proliferation inhibitory activity at 1-10 nM.  It exhibits significant anti-tumor effects in various in vivo models, and can cause complete regression of tumors at extremely low doses.  Pharmacokinetic and toxicological studies have also confirmed the good druggability and safety of YY201.

Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation inhibitor YY201 has been approved for clinical trials.webp

The clinical approval of YY201 not only represents another important breakthrough of Yuyao Biotechnology, but also verifies the innovative capabilities of Yuyao Biotech Supermolecular Glue Technology Platform and AI Drug Assisted Development Platform.  At the same time, this also proved the technical service strength of Medicilon in preclinical research.

About Yuyao Biotech
 Yuyao Biotechnology is a new drug research and development enterprise empowered by AI, led by innovation, and focusing on new technologies and new targets.  The company has three world-class new drug research and development platforms and multiple independent original product pipelines, and the core products are currently undergoing clinical research registration.  The product pipeline, YY001, targets the tumor immune microenvironment to treat PD-1 antibody-sensitive and insensitive advanced solid tumors, is about to start Phase 2 clinical research and has the potential to become the world's best immune microenvironment antagonist.  The product YY201 is the world's first transcription factor inhibitor, which is about to start phase 1 clinical research in China and the United States, and other product pipelines will soon enter clinical trials in the future.  The company has applied for more than 20 invention patents and has entered Europe, the United States, Japan, Canada, and Australia through PCT international applications.

Yuyao Biotechnology currently has more than 50 employees that hold doctor and master degrees, has more than 5,000 square meters of R&D and office space in Minhang District, Shanghai, and has completed hundreds of millions of investment in professional institutions.  Yuyao Biotech has won some awards and honors such as the National Excellence Award of the Disruptive Technology Innovation Competition of the Ministry of Science and Technology, Central Committee of the Communist Youth League "Create Youth" China Youth Innovation and Entrepreneurship Competition National Gold Award, the National Gold Award in the First Postdoctoral Innovation and Entrepreneurship Competition of the Ministry of Human Resources and Social Security and the Silver Award in the "Internet +" College Students Innovation and Entrepreneurship Competition of the Ministry of Education.

About Medicilon
Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of 2022, Medicilon has provided new drug R&D services to more than 1,840 clients around the world, and participated in the R&D of 330 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

标签：

评论

发表评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...
发表评论
阅读全文

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...
发表评论
阅读全文

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...
发表评论
阅读全文